Isabell Popp1, Maqsood Punekar2, Nick Telford3, Stavros Stivaros4,5, Kate Chandler5,6, Meenakshi Minnis5,6, Anna Castleton7, Claire Higham7,8, Louise Hopewell7, D Gareth Evans6, Anja Raams9, Arjan F Theil9, Stefan Meyer10,11,12,13,14, Detlev Schindler15. 1. Department of Human Genetics, Biozentrum, University of Wurzburg, Am Hubland, 97074, Wurzburg, Germany. 2. Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK. 3. Oncology Cytogenetics, The Christie NHS Foundation Trust, Manchester, UK. 4. Institute of Population Health, Centre for Imaging Sciences, Faculty of Medical and Human Sciences, University of Manchester, Manchester, UK. 5. Manchester Academic Health Science Centre, Manchester, UK. 6. Department of Genetic Medicine, St Mary's Hospital, Central Manchester Foundation Trust, Manchester, UK. 7. Department of Paediatric and Adolescent Oncology, The Christie NHS Foundation Trust, Manchester, UK. 8. Centre for Endocrinology and Diabetes, Institute of Human Development, Faculty of Medical and Human Sciences, University of Manchester, Manchester, UK. 9. Department of Molecular Genetics, Erasmus Medical Center, Rotterdam, The Netherlands. 10. Manchester Academic Health Science Centre, Manchester, UK. stefan.meyer@manchester.ac.uk. 11. Department of Paediatric and Adolescent Oncology, The Christie NHS Foundation Trust, Manchester, UK. stefan.meyer@manchester.ac.uk. 12. Stem Cell and Leukaemia Proteomics Laboratory, Faculty of Medical and Human Sciences, University of Manchester, Manchester, UK. stefan.meyer@manchester.ac.uk. 13. Department of Paediatric and Adolescent Oncology, Royal Manchester Children's Hospital, Manchester, UK. stefan.meyer@manchester.ac.uk. 14. Paediatric and Adolescent Oncology, Division of Cancer Sciences, University of Manchester, c/o Young Oncology Unit, Christie Hospital, Wilmslow Road, Manchester, M20 6XB, UK. stefan.meyer@manchester.ac.uk. 15. Department of Human Genetics, Biozentrum, University of Wurzburg, Am Hubland, 97074, Wurzburg, Germany. schindler@biozentrum.uni-wuerzburg.de.
Abstract
BACKGROUND: Fanconi anemia (FA) is an inherited genomic instability disorder with congenital and developmental abnormalities, bone marrow failure and predisposition to cancer early in life, and cellular sensitivity to DNA interstrand crosslinks. CASE PRESENTATION: A fifty-one-year old female patient, initially diagnosed with FA in childhood on the basis of classic features and increased chromosomal breakage, and remarkable sun-sensitivity is described. She only ever had mild haematological abnormalities and no history of malignancy. To identify and characterise the genetic defect in this lady, who is one of the oldest reported FA patients, we used whole-exome sequencing for identification of causative mutations, and functionally characterized the cellular phenotype. Detection of the novel splice site mutation c.793-2A > G and the previously described missense mutation c.1765C > T (p.Arg589Trp) in XPF/ERCC4/FANCQ assign her as the third individual of complementation group FA-Q. Ectopic expression of wildtype, but not mutant, XPF/ERCC4/FANCQ, in patient-derived fibroblasts rescued cellular resistance to DNA interstrand-crosslinking agents. Patient derived FA-Q cells showed impaired nuclear excision repair capacity. However, mutated XPF/ERCC4/FANCQ protein in our patient's cells, as in the two other patients with FA-Q, was detectable on chromatin, in contrast to XP-F cells, where missense-mutant protein failed to properly translocate to the nucleus. CONCLUSIONS: Patients with FA characteristics and UV sensitivity should be tested for mutations in XPF/ERCC4/FANCQ. The missense mutation p.Arg589Trp was previously detected in patients diagnosed with Xeroderma pigmentosum or Cockayne syndrome. Hence, phenotypic manifestations associated with this XPF/ERCC4/ FANCQ mutation are highly variable.
BACKGROUND:Fanconi anemia (FA) is an inherited genomic instability disorder with congenital and developmental abnormalities, bone marrow failure and predisposition to cancer early in life, and cellular sensitivity to DNA interstrand crosslinks. CASE PRESENTATION: A fifty-one-year old female patient, initially diagnosed with FA in childhood on the basis of classic features and increased chromosomal breakage, and remarkable sun-sensitivity is described. She only ever had mild haematological abnormalities and no history of malignancy. To identify and characterise the genetic defect in this lady, who is one of the oldest reported FA patients, we used whole-exome sequencing for identification of causative mutations, and functionally characterized the cellular phenotype. Detection of the novel splice site mutation c.793-2A > G and the previously described missense mutation c.1765C > T (p.Arg589Trp) in XPF/ERCC4/FANCQ assign her as the third individual of complementation group FA-Q. Ectopic expression of wildtype, but not mutant, XPF/ERCC4/FANCQ, in patient-derived fibroblasts rescued cellular resistance to DNA interstrand-crosslinking agents. Patient derived FA-Q cells showed impaired nuclear excision repair capacity. However, mutated XPF/ERCC4/FANCQ protein in our patient's cells, as in the two other patients with FA-Q, was detectable on chromatin, in contrast to XP-F cells, where missense-mutant protein failed to properly translocate to the nucleus. CONCLUSIONS:Patients with FA characteristics and UV sensitivity should be tested for mutations in XPF/ERCC4/FANCQ. The missense mutation p.Arg589Trp was previously detected in patients diagnosed with Xeroderma pigmentosum or Cockayne syndrome. Hence, phenotypic manifestations associated with this XPF/ERCC4/ FANCQ mutation are highly variable.
Entities:
Keywords:
DNA repair; ERCC4; FANCQ; Fanconi anemia; UV sensitivity; XPF
Authors: David I Kutler; Krupa R Patel; Arleen D Auerbach; Jennifer Kennedy; Francis P Lach; Erica Sanborn; Marc A Cohen; William I Kuhel; Agata Smogorzewska Journal: Laryngoscope Date: 2015-10-20 Impact factor: 3.325
Authors: Massimo Bogliolo; Beatrice Schuster; Chantal Stoepker; Burak Derkunt; Yan Su; Anja Raams; Juan P Trujillo; Jordi Minguillón; María J Ramírez; Roser Pujol; José A Casado; Rocío Baños; Paula Rio; Kerstin Knies; Sheila Zúñiga; Javier Benítez; Juan A Bueren; Nicolaas G J Jaspers; Orlando D Schärer; Johan P de Winter; Detlev Schindler; Jordi Surrallés Journal: Am J Hum Genet Date: 2013-04-25 Impact factor: 11.025
Authors: Laura J Niedernhofer; George A Garinis; Anja Raams; Astrid S Lalai; Andria Rasile Robinson; Esther Appeldoorn; Hanny Odijk; Roos Oostendorp; Anwaar Ahmad; Wibeke van Leeuwen; Arjan F Theil; Wim Vermeulen; Gijsbertus T J van der Horst; Peter Meinecke; Wim J Kleijer; Jan Vijg; Nicolaas G J Jaspers; Jan H J Hoeijmakers Journal: Nature Date: 2006-12-21 Impact factor: 49.962
Authors: Helmut Hanenberg; Sat Dev Batish; Karen E Pollok; Lydia Vieten; Peter C Verlander; Cordula Leurs; Ryan J Cooper; Kerstin Göttsche; Laura Haneline; D Wade Clapp; Stephan Lobitz; David A Williams; Arleen D Auerbach Journal: Exp Hematol Date: 2002-05 Impact factor: 3.084
Authors: A M Sijbers; W L de Laat; R R Ariza; M Biggerstaff; Y F Wei; J G Moggs; K C Carter; B K Shell; E Evans; M C de Jong; S Rademakers; J de Rooij; N G Jaspers; J H Hoeijmakers; R D Wood Journal: Cell Date: 1996-09-06 Impact factor: 41.582
Authors: David I Kutler; Arleen D Auerbach; Jaya Satagopan; Philip F Giampietro; Sat Dev Batish; Andrew G Huvos; Andy Goberdhan; Jatin P Shah; Bhuvanesh Singh Journal: Arch Otolaryngol Head Neck Surg Date: 2003-01
Authors: Hiva Fassihi; Mieran Sethi; Heather Fawcett; Jonathan Wing; Natalie Chandler; Shehla Mohammed; Emma Craythorne; Ana M S Morley; Rongxuan Lim; Sally Turner; Tanya Henshaw; Isabel Garrood; Paola Giunti; Tammy Hedderly; Adesoji Abiona; Harsha Naik; Gemma Harrop; David McGibbon; Nicolaas G J Jaspers; Elena Botta; Tiziana Nardo; Miria Stefanini; Antony R Young; Robert P E Sarkany; Alan R Lehmann Journal: Proc Natl Acad Sci U S A Date: 2016-02-16 Impact factor: 11.205
Authors: Shreya M Shah; Elena V Demidova; Randy W Lesh; Michael J Hall; Mary B Daly; Joshua E Meyer; Martin J Edelman; Sanjeevani Arora Journal: Cancer Treat Rev Date: 2022-01-05 Impact factor: 13.608